Author

D. Schaefer-Babajew

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 7 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 8 Organism:human· 8 Assay:proteomics· 8 Research Focus:cell type annotation· 4 Research Focus:clustering· 3 Research Focus:differential expression· 2 Assay:flow cytometry· 2

Frequent Co-Authors

C. Gaebler· 9 shared M. Caskey· 9 shared F. Schmidt· 8 shared T. Hatziioannou· 8 shared A. Cho· 7 shared A. Gazumyan· 7 shared F. Muecksch· 7 shared M. C. Nussenzweig· 7 shared

Activity by Year

2020-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersImmunology

C. Gaebler

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine

A. Cho, F. Muecksch, Z. Wang, T. Ben Tanfous, J. DaSilva, R. Raspe, B. Johnson, E. Bednarski, V. Ramos, D. Schaefer-Babajew, I. Shimeliovich, J. Dizon, K.-H. Yao, F. Schmidt, K. G. Millard, , M. C. Nussenzweig

This study compares memory B cell responses after single-dose Ad26.COV2.S and mRNA vaccines, finding lower quantities but comparable neutralizing quality in Ad26.COV2.S recipients.

bioRxiv · Mar 31, 2022Immunology

Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose

F. Muecksch, Z. Wang, A. Cho, C. Gaebler, T. Ben Tanfous, J. DaSilva, E. Bednarski, V. Ramos, S. Zong, B. Johnson, R. Raspe, D. Schaefer-Babajew, I. Shimeliovich, M. Daga, K.-H. Yao, , M. Nussenzweig

This study shows that a third mRNA vaccine dose increases the potency and breadth of SARS-CoV-2 neutralizing antibodies, particularly against the Omicron variant, through the expansion and evolution of memory B cells.

bioRxiv · Feb 14, 2022 · PreprintImmunology

High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies

F. Schmidt, Y. Weisblum, M. Rutkowska, D. Poston, J. Da Silva, F. Zhang, E. Bednarski, A. Cho, D. Schaefer-Babajew, C. Gaebler, M. Caskey, M. C. Nussenzweig, T. Hatziioannou, P. D. Bieniasz

This study shows that multiple neutralizing epitopes in SARS-CoV-2 spike proteins are targeted by polyclonal antibodies, and 20 mutations can confer resistance, but vaccinated and infected individuals' plasma neutralizes these resistant variants and diverse sarbecoviruses.

bioRxiv · Aug 6, 2021Microbiology

Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination

A. Cho, F. Muecksch, D. Schaefer-Babajew, Z. Wang, S. Finkin, C. Gaebler, V. Ramos, M. Cipolla, P. Mendoza, M. Agudelo, E. Bednarski, J. DaSilva, I. Shimeliovich, J. Dizon, M. Daga, , M. C. Nussenzweig

This study examines memory B cell evolution 5 months after mRNA vaccination in naive individuals, finding increased neutralizing activity but no further breadth or potency, and higher overall plasma neutralizing potency compared to natural infection.

bioRxiv · Jul 29, 2021Immunology

Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year

Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H.- H. Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. D. Silva, E. Bednarski, , M. C. Nussenzweig

This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.

Nature · Jun 14, 2021Peer-reviewedImmunology

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

F. Muecksch, Y. Weisblum, C. Barnes, F. Schmidt, D. Schaefer-Babajew, J. Lorenzi, A. Flyak, A. DeLaitsch, K. Huey-Tubman, S. Hou, C. Schiffer, C. Gaebler, Z. Wang, J. Da Silva, D. Poston, , P. Bieniasz

This study examines how somatic mutations in SARS-CoV-2 antibodies affect their neutralization potency, breadth, and resistance to escape mutations across six antibody lineages.

bioRxiv · Mar 7, 2021 · PreprintMicrobiology

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, , M. C. Nussenzweig

This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.

Nature · Feb 10, 2021Peer-reviewedImmunology

Persistent Cellular Immunity to SARS-CoV-2 Infection

G. Breton, P. Mendoza, T. Hagglof, T. Y. Oliveira, D. Schaefer-Babajew, C. Gaebler, M. Turroja, A. Hurley, M. Caskey, M. C. Nussenzweig

The paper shows that SARS-CoV-2 infection leads to persistent, functional memory T cell responses and enduring immune alterations in CD4+ and CD8+ T cells six months post-infection.

bioRxiv · Dec 8, 2020Immunology

Evolution of Antibody Immunity to SARS-CoV-2

C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, A. Hurley, M. Turroja, , R. Patel

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

bioRxiv · Nov 3, 2020Immunology